Anzeige
Mehr »
Login
Freitag, 10.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
100 % Anstieg in zwei Tagen: Das technische Signal, das Wall Streets Bären in Panik versetzt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
461 Leser
Artikel bewerten:
(2)

Netigate AB: Co-founder and former CEO of Snow Software joins Netigate as Chairman to stimulate growth

Finanznachrichten News

Renowned SaaS entrepreneur to join experience management organisation's board to propel strategy forward.

STOCKHOLM, Feb. 16, 2023 /PRNewswire/ -- Netigate, one of Europe's leading experience management organisations, announced today that Axel Kling, the co-founder and former CEO of Snow Software, is joining its board of directors as Chairman. Kling will step into this pivotal governance role to steer the board's agenda, support the shareholders' goals, and enable the company to continue an ambitious growth trajectory.

This news comes during a period of rapid expansion for Netigate. In August 2022, the company announced that the Nordic-based private equity firm GRO Capital had become the new majority shareholder. Together with GRO, and now with Kling at the helm of the board, Netigate will continue to provide customers with innovative experience management solutions backed by cutting-edge technology and human expertise.

Kling will partner with the board and Netigate's CEO, Mikkel Drucker, to set the strategic direction and keep the leadership team laser-focused on reaching priorities. He also aspires to act as a sounding board, a spokesperson, and a connector for the CEO and rest of the leadership team to facilitate smooth operations.

Axel Kling, Chairman, comments: "I was really compelled by the customer challenge Netigate is solving. We tend to get absorbed with what I normally call inside out thinking: mainly focusing on our team or company objectives without looking outside of this reality. The more we grow, the more we have to be able to step outside of our own little bubble and look at ourselves from the outside in-this has always been my quest during my career. Netigate offers a solution to this universal problem: a platform to ask the right questions, to capture opinions and feelings, and ultimately, to give every voice value. Everyone talks about the need for data and the importance of seeking feedback, so it's exciting to join a team who walks the talk."

"Netigate will undoubtedly prosper from Axel's exceptional history of scaling an international company and elevating it from a start-up to a rapidly growing mature organization," says Mikkel Drucker, CEO of Netigate. "I'm eager to work with Axel and humbly anticipate learning from and being inspired by his achievements."

"We are very excited to have Axel on our board," adds Lars Lunde, Partner at GRO. "His extensive experience in building and growing SaaS companies will be a great asset as we continue to expand Netigate's presence globally."

Kling co-founded Snow Software in 2001 and led the company as CEO until 2019, building the company into a Gartner quadrant leader with 800+ employees, turning over $150M+ a year. Kling remains on the board of Snow and has since 2019 assumed various board positions for SaaS companies on ambitious growth paths.

CONTACT:

Press contact:
Natasha Ellis-Knight
Marketing Manager
Natasha.ellisknight@netigate.net

The following files are available for download:

https://news.cision.com/netigate-ab/i/axel-kling-netigate-chairman-2023,c3145006

Axel Kling Netigate Chairman 2023

Cision View original content:https://www.prnewswire.co.uk/news-releases/co-founder-and-former-ceo-of-snow-software-joins-netigate-as-chairman-to-stimulate-growth-301748631.html

© 2023 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Diesen Artikel auf Deutsch lesen
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.